Renal denervation (RDN) in patients with treatment resistant hypertension. 2nd Update
Goetz G, Giess D, Kern J
Record ID 32018013187
English
Authors' objectives:
Treatment-resistant hypertension (TRH) is diagnosed when blood pressure remains above 140/90 mmHg systolic/diastolic despite lifestyle changes and the use of at least three antihypertensive agents at maximum tolerated doses. Renal denervation (RDN) is a minimally invasive procedure in which the sympathetic nerves along the renal artery are obliterated to lower blood pressure.
Authors' results and conclusions:
A total of ten RCTs comparing RDN with sham therapy were included to assess the efficacy and safety of RDN. Overall, the current evidence suggests that RDN is effective in lowering blood pressure for up to six months after the intervention and is relatively safe. It remains unclear however, which patients benefit most from RDN and how long the blood pressure-lowering effect persists.
Details
Project Status:
Completed
Year Published:
2024
URL for published report:
https://eprints.aihta.at/1529/1/DSD_45_Update2024.pdf
URL for additional information:
https://eprints.aihta.at/1529/
English language abstract:
An English language summary is available
Publication Type:
Full HTA
Country:
Austria
MeSH Terms
- Denervation
- Renal Artery
- Kidney
- Hypertension
- Blood Pressure
- Sympathectomy
Keywords
- Renal denervation
- treatment resistant hypertension
- catheter ablation
- kidney innervation
Contact
Organisation Name:
Austrian Institute for Health Technology Assessment
Contact Address:
Garnisongasse 7/20, A-1090 Vienna, Austria
Contact Name:
office@aihta.at
Contact Email:
office@aihta.at
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.